论文部分内容阅读
目的:比较MLH1、MSH2和PMS2、MSH6两种抗体组合在子宫内膜癌(EC)MMR蛋白表达缺失的敏感性,优化检测EC中MMR蛋白表达缺失的抗体组合。方法:选取126例EC肿瘤组织,应用免疫组化法检测EC中MLH1、MSH2、PMS2和MSH6蛋白的表达。结果:126例子宫内膜癌中MLH1和MSH2蛋白缺失的检出率为22.22%(28/126),PMS2和MSH6蛋白缺失的漏诊率为6.35%(8/126);PMS2和MSH6蛋白缺失的检出率为29.37%(37/126),MLH1和MSH2蛋白缺失的漏诊率为5.56%(7/126)。结论:应用MLH1、MSH2和PMS2、MSH6两种抗体组合均不能完全检测到MMR蛋白的表达缺失,仍需联合应用四种抗体检测EC中MMR蛋白的表达缺失,防止某一种MMR蛋白表达缺失病例的漏诊。
OBJECTIVE: To compare the sensitivity of MLH1, MSH2, PMS2 and MSH6 in the loss of MMR protein expression in endometrial carcinoma (EC) and to optimize the combination of antibodies for detecting the absence of MMR protein expression in EC. Methods: 126 EC tissues were selected and the expressions of MLH1, MSH2, PMS2 and MSH6 in EC were detected by immunohistochemistry. Results: The detection rate of MLH1 and MSH2 protein deletion in 126 cases of endometrial carcinoma was 22.22% (28/126), and the missed diagnosis rate of PMS2 and MSH6 protein deletion was 6.35% (8/126). The deletion of PMS2 and MSH6 protein The detection rate was 29.37% (37/126). The misdiagnosis rate of MLH1 and MSH2 protein deletion was 5.56% (7/126). CONCLUSION: The combination of MLH1, MSH2, PMS2 and MSH6 can not detect the MMR protein expression loss completely. Four antibodies should be used in combination to detect the absence of MMR protein in EC and prevent the deletion of one MMR protein. Misdiagnosis.